---
schema_version: "secwatch.filing_event.v1"
accession: "0001140361-25-032502"
form_type: "8-K"
ticker: "RCKT"
cik: "0001281895"
company_name: "ROCKET PHARMACEUTICALS, INC."
filed_at: "2025-08-25T23:59:59+00:00"
generated_at: "2026-05-17T10:09:53.673846+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Rocket Pharma CFO resigns; General Counsel named interim CFO

## Summary
- Aaron Ondrey resigned as CFO effective September 5, 2025 to pursue other opportunities.
- Martin Wilson, General Counsel and Chief Corporate Officer, appointed interim Principal Financial Officer effective September 8, 2025.
- Wilson joined Rocket in November 2021; has nearly 20 years of life sciences legal and executive experience.
- No family relationships or transactions with the company beyond compensation for current roles.

## SEC filing metadata
- accession: 0001140361-25-032502
- form_type: 8-K
- ticker: RCKT
- cik: 0001281895
- company_name: ROCKET PHARMACEUTICALS, INC.
- filed_at: 2025-08-25T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1281895/000114036125032502/0001140361-25-032502-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1281895/000114036125032502/ef20054457_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001140361-25-032502
- JSON: https://secwatch.observer/filing/0001140361-25-032502.json
- Plain text: https://secwatch.observer/filing/0001140361-25-032502.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.